公开(公告)号：JP2010194323A

公开(公告)日：2010-09-09

申请号：JP2010052515

申请日：2010-03-10

Applicant: Celltech R & D Ltd ,  Oxford Instruments Superconductivity Ltd ,  オックスフォード インストゥルメンツ スーパーコンダクティビティー リミテッド ,  セルテック アール アンド ディ リミテッド

Inventor： SLADE ROBERT ANDREW ,  EATON MICHAEL

IPC: A61N2/00 ,  A61K9/14 ,  A61K33/24 ,  A61K33/26 ,  A61K41/00 ,  A61K47/42 ,  A61K49/18 ,  A61N1/40 ,  A61N2/08

CPC classification number: B82Y5/00 ,  A61K41/00 ,  A61K47/6923 ,  A61K47/6929 ,  A61N1/406

Abstract: PROBLEM TO BE SOLVED: To provide an improved process using magnetic particles for inducing cell death which is not dependent on high strength and/or high frequency variation of a magnetic field, and also on the procedure for inducing local or overall temperature rise in a tissue. SOLUTION: Magnetic particles are used in therapeutic applications to disrupt biological materials. The particles have intrinsic magnetization, and this magnetization is stabilized by inherent magneto-crystal line anisotropy and/or shape anisotropy. By applying a magnetic field, the magnetic particles are induced to rotate when localized at a target biological material, thereby disrupting this material. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：提供一种使用磁性粒子诱导细胞死亡的改进方法，其不依赖于磁场的高强度和/或高频率变化，以及诱导局部或总体升温的程序 在一个纸巾。

解决方案：磁性颗粒用于治疗应用以破坏生物材料。 颗粒具有固有的磁化，并且该磁化通过固有的磁 - 晶线各向异性和/或形状各向异性来稳定。 通过施加磁场，当定位在目标生物材料时，磁性颗粒被诱导旋转，从而破坏该材料。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009057371A

公开(公告)日：2009-03-19

申请号：JP2008188089

申请日：2008-07-22

Applicant: Celltech R & D Ltd ,  セルテック アール アンド ディ リミテッド

Inventor： BAILEY STUART ,  BROWN JULIEN ALISTAIR ,  BRAND STEPHEN ,  JOHNSON JAMES ANDREW ,  PORTER JOHN ROBERT ,  HEAD JOHN CLIFFORD

IPC: C07C229/36 ,  A61K31/198 ,  A61K31/223 ,  A61K31/352 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07C229/34 ,  C07C229/46 ,  C07C233/81 ,  C07C233/82 ,  C07C321/22 ,  C07C323/30 ,  C07D213/81 ,  C07D213/89 ,  C07D311/96 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

CPC classification number: C07D213/81 ,  C04B35/632 ,  C07C229/10 ,  C07C229/46 ,  C07C233/81 ,  C07C233/82 ,  C07C323/30 ,  C07C2601/04 ,  C07C2603/94 ,  C07C2603/96 ,  C07D213/79 ,  C07D213/89 ,  C07D311/96 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

Abstract: PROBLEM TO BE SOLVED: To provide a compound inhibiting the binding of integrin with a ligand and useful in the prevention and treatment of immune or inflammatory diseases associated with inappropriate cell proliferation or migration. SOLUTION: The compound is represented by formula (1) and is exemplified by 3-oxocyclobut-1-enylamino-group-containing methyl(2S)-2-ä(3-oxospiro[3,5]-non-1-en-1-yl)amino}-3-(2,6-dimethoxy[1,1'-biphenyl]-4-yl)propanoate. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 要解决的问题：提供抑制整联蛋白与配体结合并可用于预防和治疗与不适当细胞增殖或迁移相关的免疫或炎性疾病的化合物的问题。 解决方案：化合物由式（1）表示，并且例示为含有3-氧代环丁-1-烯基氨基的（2S）-2-（3-氧代螺[3,5] - 壬-1 丁-1-基）氨基} -3-（2,6-二甲氧基[1,1'-联苯] -4-基）丙酸乙酯。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：JP2007105043A

公开(公告)日：2007-04-26

申请号：JP2006285205

申请日：2006-10-19

Applicant: Celltech R & D Ltd ,  セルテック アール アンド ディ リミテッド

Inventor： ATHWAL DILJEET S ,  BROWN DEREK T ,  CHARLES WEIR ANDREW NEIL ,  POPPLEWELL ANDREW G ,  CHAPMAN ANDREW P ,  KING DAVID J

IPC: C12N15/09 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53

CPC classification number: C07K16/241 ,  A61K47/6845 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

Abstract: PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity for the antigenic determinant of a human tumor necrosis factor α(TNFα), and to provide a curative use of the antibody molecule, and to provide a method for producing the same. SOLUTION: The antibody molecule contains at least one CDR(complementarity determining region) derived from a mouse monoclonal antibody having specificity for the antigenic determinant of a human TNFα. A CDR-grafted antibody wherein at least one of the CDRs is a hybrid CDR is also provided. Furthermore, DNA sequences encoding the chains of the antibody molecules, vectors, and transformed host cells are provided, respectively. Another version of the above antibody molecule covalent-bonded with a methoxypoly(ethylene glycol) residue is also provided. Besides, uses of these antibody molecules in the treatment of diseases mediated by TNFα are provided. COPYRIGHT: (C)2007,JPO&INPIT

Abstract translation: 要解决的问题：提供对人肿瘤坏死因子α（TNFα）的抗原决定簇具有特异性的抗体分子，并提供抗体分子的治疗用途，并提供其制备方法 。 解决方案：抗体分子含有至少一种衍生自对人TNFα的抗原决定簇具有特异性的小鼠单克隆抗体的CDR（互补决定区）。 还提供了其中至少一个CDR是杂交CDR的CDR移植抗体。 此外，分别提供编码抗体分子，载体和转化的宿主细胞的链的DNA序列。 还提供了与甲氧基聚（乙二醇）残基共价键合的上述抗体分子的另一版本。 此外，提供了这些抗体分子在治疗TNFα介导的疾病中的用途。 版权所有（C）2007，JPO＆INPIT

公开(公告)号：WO2005046657A3

公开(公告)日：2005-11-03

申请号：PCT/GB2004004652

申请日：2004-11-03

Applicant: CELLTECH R&D LTD ,  LAWSON ALASTAIR DAVID GRIFFITH ,  BOURNE TIMOTHY

Inventor： LAWSON ALASTAIR DAVID GRIFFITH ,  BOURNE TIMOTHY

IPC: A61K31/00 ,  A61K39/395 ,  C07K16/24 ,  A61P29/00

CPC classification number: C07K16/243 ,  A61K31/00 ,  A61K2039/505 ,  C07K2317/24

Abstract: The present invention provides a method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity.

Abstract translation: 本发明提供了治疗和/或预防炎症性肠病（IBD）的方法，其包括给予治疗有效量的CSF-1活性抑制剂。

公开(公告)号：WO03045901A3

公开(公告)日：2003-07-31

申请号：PCT/GB0300339

申请日：2003-01-28

Applicant: CELLTECH R&D LTD ,  DYKE HAZEL JOAN ,  BUCKLEY GEORGE MARTIN

Inventor： DYKE HAZEL JOAN ,  BUCKLEY GEORGE MARTIN

IPC: A61P35/02 ,  C07D263/32 ,  C07D413/12 ,  C07D417/12 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427

CPC classification number: C07D413/12 ,  C07D263/32 ,  C07D417/12

Abstract: Guanidine derivatives of formula I are described: wherein: R' is an aliphatic, cycloaliphatic or cycloalkyl-alkyl- group R2 is an optionally substituted aromatic, heteroaromatic group, aryl-fused cycloaliphatic, heteroaryl-fused cycloaliphatic, aryl-fused heterocycloaliphatic or heteroaryl-fused heterocycloaliphatic group R3 is a -CN, -COR5, -OR6, -CONR7R8, S02R5 or S02NR7R8 group R4 is an optionally substituted heteroaromatic group and the salts, solvates, hydrates, tautomers, isomers, N-oxides thereof. The compounds are potent inhibitors of IMPDH and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatic and anti-viral agents.

Abstract translation: 描述了式I的胍衍生物：其中：R'是脂族，脂环族或环烷基 - 烷基 - 基团，R2是任选取代的芳族，杂芳族基团，芳基稠合的脂环族，杂芳基稠合的脂环族，芳基稠合的杂环脂族基或杂芳基 - 稠合的杂环脂族基团R 3是-CN，-COR 5，-OR 6，-CONR 7 R 8，SO 2 R 5或SO 2 NR 7 R 8基团，R 4是任选取代的杂芳族基团及其盐，溶剂合物，水合物，互变异构体，异构体，N-氧化物。 该化合物是IMPDH的有效抑制剂，并且可用作免疫抑制剂，抗癌剂，抗炎剂，抗银屑病剂和抗病毒剂。

公开(公告)号：WO03004636A3

公开(公告)日：2003-06-26

申请号：PCT/GB0203129

申请日：2002-07-05

Applicant: CELLTECH R&D LTD ,  HUMPHREYS DAVID PAUL

Inventor： HUMPHREYS DAVID PAUL

IPC: C12N15/09 ,  C07K16/00 ,  C12N1/21 ,  C12N9/16 ,  C12N9/64 ,  C12N15/13 ,  C12N15/34 ,  C12P21/08 ,  C12N15/70

CPC classification number: C12N9/6424 ,  C07K16/00 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/02 ,  C12N9/16

Abstract: Expression vectors encoding bacteriophage signal peptides are described. The vectors may be used for the heterologous expression and secretion of polypeptides such as antibodies in bacterial host cells.

Abstract translation: 描述编码噬菌体信号肽的表达载体。 载体可用于在细菌宿主细胞中异源表达和分泌多肽，例如抗体。

公开(公告)号：WO0179173A2

公开(公告)日：2001-10-25

申请号：PCT/GB0101682

申请日：2001-04-12

Applicant: CELLTECH R&D LTD ,  NORMAN TIMOTHY JOHN ,  PORTER JOHN ROBERT ,  HUTCHINSON BRIAN WOODSIDE ,  RATCLIFFE ANDREW JAMES ,  HEAD JOHN CLIFFORD ,  ALEXANDER RIKKI PETER ,  LANGHAM BARRY JOHN ,  WARRELLOW GRAHAM JOHN ,  ARCHIBALD SARAH CATHERINE ,  LINSLEY JANEEN MARSHA

Inventor： NORMAN TIMOTHY JOHN ,  PORTER JOHN ROBERT ,  HUTCHINSON BRIAN WOODSIDE ,  RATCLIFFE ANDREW JAMES ,  HEAD JOHN CLIFFORD ,  ALEXANDER RIKKI PETER ,  LANGHAM BARRY JOHN ,  WARRELLOW GRAHAM JOHN ,  ARCHIBALD SARAH CATHERINE ,  LINSLEY JANEEN MARSHA

IPC: A61K31/198 ,  A61K31/223 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4436 ,  A61K31/4545 ,  A61K31/472 ,  A61P1/04 ,  A61P3/10 ,  A61P11/06 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07C229/36 ,  C07D213/81 ,  C07D217/22 ,  C07D409/12 ,  C07D471/04 ,  A61K31/44 ,  C07C225/20

CPC classification number: C07D213/81 ,  C07C229/36 ,  C07C2601/10 ,  C07D217/22 ,  C07D471/04

Abstract: Enamine derivatives of formula (1) are described. In said formula , R a group Ar L Ar Alk- in which Ar is an aromatic or heteroaromatic group, L is a covalent bond or a linker atom or group, Ar is an arylene or heteroarylene group and Alk is a chain -CH2-CH(R)-, -CH=C(R)- or (a) in which R is a carboxylic acid or a derivative or biostere thereof; R is a hydrogen atom or a C1-6alkyl group; Cy is a cycloaliphatic or heterocycloaliphatic ring in which X is a N atom or a C(R ) group; R is a oxo, thioxo, or imino group; R and R are each a hydrogen atom or optional substituent; provided that Cy is not a cyclobutenedione group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.

Abstract translation: 描述式（1）的烯胺衍生物。 在所述式中，R 1，Ar 1，Ar 2，Ar 2 Al，其中Ar 1是芳族或杂芳族基团，L 2是共价键或连接原子或 基团，Ar 2是亚芳基或亚杂芳基，Alk是链-CH 2 -CH（R） - ， - CH = C（R） - 或（a）其中R是羧酸或衍生物或生物固体 物; R 2是氢原子或C 1-6烷基; Cy是其中X是N原子或C（R））基团的脂环族或杂脂环族环; R x是氧代，硫代或亚氨基; R w和R z各自为氢原子或任选的取代基; 只要Cy不是环丁烯二酮基团; 及其盐，溶剂合物，水合物和N-氧化物。 这些化合物能够抑制整联蛋白与其配体的结合，并且可用于预防和治疗免疫或炎性疾病或涉及细胞不适当生长或迁移的病症。

公开(公告)号：WO2006000753A3

公开(公告)日：2006-04-06

申请号：PCT/GB2005002389

申请日：2005-06-17

Applicant: CELLTECH R&D LTD ,  STAMPS ALASDAIR

Inventor： STAMPS ALASDAIR

IPC: C07K14/47 ,  A61K38/17 ,  A61P35/00 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K38/1709 ,  C07K14/47 ,  G01N33/574 ,  G01N2500/04

Abstract: The present invention relates to new uses of FLJ40787 in the diagnosis, screening, treatment and prophylaxis of colon cancer, colorectal cancer, ovarian cancer, lung cancer and/or liver cancer cancer. The invention also provides compositions comprising FLJ40787, including vaccines, antibodies that are immunospecific for FLJ40787 and agents which interact with or modulate the expression or activity of FLJ40787 or which modulate the expression of the nucleic acid which codes for FLJ40787.

Abstract translation: 本发明涉及FLJ40787在结肠癌，结肠直肠癌，卵巢癌，肺癌和/或肝癌癌症的诊断，筛选，治疗和预防中的新用途。 本发明还提供了包含FLJ40787的组合物，包括疫苗，针对FLJ40787免疫特异性的抗体和与FLJ40787相互作用或调节FLJ40787的表达或活性或调节编码FLJ40787的核酸表达的试剂。

公开(公告)号：WO2005003171A3

公开(公告)日：2005-09-29

申请号：PCT/GB2004002871

申请日：2004-07-01

Applicant: CELLTECH R&D LTD ,  HEYWOOD SAM PHILIP ,  HUMPHREYS DAVID PAUL

Inventor： HEYWOOD SAM PHILIP ,  HUMPHREYS DAVID PAUL

IPC: C07K16/00 ,  A61K39/395

CPC classification number: C07K16/00 ,  C07K2317/55

Abstract: The present invention relates to a new class of antibody fragments including antibody Fab and Fab' fragments in which the heavy chain is not covalently bonded to the light chain and two or more effector molecules are attached to the fragment, of which at least one of said molecules is attached to a cysteine in the heavy or light chain constant region.

Abstract translation: 本发明涉及一类新的抗体片段，包括抗体Fab和Fab'片段，其中重链不与轻链共价结合，并且两个或多个效应分子与片段连接，其中至少一个所述 分子与重链或轻链恒定区中的半胱氨酸连接。

公开(公告)号：WO2005003169A3

公开(公告)日：2005-05-06

申请号：PCT/GB2004002810

申请日：2004-07-01

Applicant: CELLTECH R&D LTD ,  HUMPHREYS DAVID PAUL ,  HEYWOOD SAM PHILIP

Inventor： HUMPHREYS DAVID PAUL ,  HEYWOOD SAM PHILIP

IPC: C07K16/00 ,  A61K39/395

CPC classification number: C07K16/00 ,  A61K2039/505 ,  C07K2317/55

Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.

Abstract translation: 本发明提供了其中重链恒定区终止于CH1的链间半胱氨酸的抗体Fab片段。 还提供了抗体Fab片段，其中重链恒定区在CH1的链间半胱氨酸处终止于一个或多个效应分子所连接的CH1的链间半胱氨酸。